Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of$ 0.98. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.20%. A quarter ago, it was expected that this company would post a loss of$ 1.15 per share when it actually produced a loss of $1.01, delivering a surprise of 12.17%. Over the last four quarters, the compa ...